comparemela.com

Latest Breaking News On - Terufumi kato - Page 1 : comparemela.com

Investigators Deliver Updates on Evolving Clinical Trials Evaluating ADCs in Lung Cancer

Dr Kato on the Rationale For Investigating Dato-DXd Plus Durvalumab and Carboplatin in Advanced NSCLC

Terufumi Kato, MD, Terufumi Kato, MD, Chief Physician, Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan, discusses the ongoing investigation of datopotamab deruxtecan in combination with durvalumab and carboplatin as a first-line treatment for patients with advanced metastatic non–small cell lung cancer.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.